{"id":"nct:NCT07424404","kind":"trial","title":"A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents","authors":["Karuna Therapeutics, Inc., a Bristol Myers Squibb company"],"author_count":1,"year":2026,"published":"2026-02-20","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07424404","source_url":"https://clinicaltrials.gov/study/NCT07424404","archive_url":"https://space-kitty.com/papers/nct:NCT07424404","updated":"2026-10-15","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Schizophrenia","Autism-Related Irritability"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":400,"sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","conditions":["Schizophrenia","Autism-Related Irritability"],"interventions":["DRUG: KarXT","DRUG: KarX-EC"],"start_date":"2026-04-07","start_date_type":"ACTUAL","primary_completion_date":"2030-03-08","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}